Molecular Cytogenetics Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global molecular cytogenetics market, valued at US$2.8 billion in 2022, is forecasted to grow at a robust CAGR of 9.9%, reaching US$3.1 billion in 2023 and an impressive US$4.9 billion by 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Investments by diagnostic labs and research centers, expanding units, and improved cous on targeted medicine are expected to boost the market for molecular cytogenetics. Moreover, increased demand for new techniques is expected to increase in the coming years, which is expected to propel the global market growth.

Attractive Opportunities in the Molecular Cytogenetics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Molecular Cytogenetics Market Dynamics

DRIVER: Increasing incidence of cancer and genetic disorders

The global rise in cancer cases is notable. Studies have revealed recurrent genomic abnormalities in human diseases over the past twenty years, potentially contributing significantly to the growth of cancer. According to the cancer report released by the Indian Council of Medical Research (ICMR) and the National Centre for Disease Informatics and Research (NCDIR) in 2020, cancer cases in India are estimated to increase by 12% by 2025. Though individual genetic disorders are rare, they comprise over 15,500 recognized genetic disorders collectively. According to the WHO, in 2023, 3–4% of all births consisted of congenital malformations and 20–30% of all infant deaths were caused due to genetic disorders. Over the years, the prevalence of genetic disorders such as diabetes and rheumatoid arthritis has risen rapidly across the globe.

RESTRAINT: High cost of advanced instruments

The instruments required for cytogenetics come at a high cost due to their incorporation of advanced technologies and features. Additionally, there are ongoing expenses related to maintenance and insurance. An average molecular diagnostic instrument costs between USD 10.000 and USD 20,000. Due to their exorbitant expenses, smaller companies and research institutes with limited R&D budgets find it challenging to acquire or create such costly instruments. Another significant hurdle is the intricate nature of manufacturing kits, reagents, probes, and instruments. The development process for cytogenetics products is exceedingly intricate and costly, demanding substantial investments, technical expertise, proficiency in clinical trials, adherence to scientific standards, and robust quality systems.

OPPORTUNITY: Untapped emerging markets

Due to their exorbitant expenses, smaller companies and research institutes with limited R&D budgets find it challenging to acquire or create such costly instruments. Another significant hurdle is the intricate nature of manufacturing kits, reagents, probes, and instruments. The development process for cytogenetics products is exceedingly intricate and costly, demanding substantial investments, technical expertise, proficiency in clinical trials, adherence to scientific standards, and robust quality systems.To meet the increasing demand for cytogenetic products in emerging markets, manufacturers are strategically focusing on geographical expansions to strengthen their market position in these regions.

CHALLENGE: Transition from FISH to array-based techniques

The FISH techniques were partly replaced by the introduction of comparative genomic hybridization (CGH) in 1992. Being time-consuming and expensive to evaluate chromosomal rearrangements in FISH, array based CGH was developed. Emergence of new technologies for faster hybridization of the genome during array-based techniques is expected to create great opportunities for growth of the global market. Also, array-based techniques have wider applications such as CGX Onco Arrays from Perkinelmer, Inc. (Revvity) are microarrays specifically designed, developed for the detection of small genetic aberrations associated with hematological disorders such as leukemias and lymphomas, as well as genes associated with solid tumors.

Molecular Cytogenetics Ecosystem Market Ecosystem/Map

Kits & Reagents segment accounted for the largest share of the molecular cytogenetics industry in 2022, by product.

The molecular cytogenetics market is categorized into kits & reagents, instruments, consumables and software & services based on product. The kits & reagents segment emerged as the dominant force in the in 2022. The market is being driven by technological advancements coupled with launch of new molecular cytogenetics kits and increasing incidence of cancer.

Comparative genomic hybridization segment accounted for the largest share of the molecular cytogenetics industry in 2022, by technique.

The molecular cytogenetics market is categorized into comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques based on technique. The comparative genomic hybridization segment emerged as the dominating segment in the market in 2022. The market is being driven by increasing penetration of molecular cytogenetics in clinical pathological testing coupled with increasing research need of molecular cytogenetics products for the development of personalized medicines..

Cancer segment accounted for the largest share in the Increasing penetration of molecular cytogenetics in molecular cytogenetics industry in 2022, by application.

The global Increasing penetration of molecular cytogenetics market is categorized into genetic disorders, cancer, personalized medicine and other applications based on application. In 2022, the cancer segment held the largest share in the market, categorized by application. Throughout the world, cancer stands as a prominent cause of mortality and genetics is a major cause od majority of the chronic diseases like diabetes. Early identification and treatment play a crucial role in minimizing additional diseases like kidney, liver, etc. Therefore, the growing incidence of genetic and cancer related diseases coupled with the health complications associated with them is driving the demand for technologically advanced diagnostic tests, which, in turn, is propelling the market for molecular cytogenetics.

Clinical & research laboratories segment accounted for the largest share in the molecular cytogenetics industry in 2022, by end user.

Based on end user, the molecular cytogenetics market has been segmented into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users. In 2022, clinical & research laboratories segment accounted for the largest share of the market. Cancer and genetic diorders diagnostic services are available in clinics laboratories coupled with major usage in the research and academic labs. These facilities boast advantages such as enhanced and specialized testing options, streamlined billing systems, and cost-effectiveness. Additionally, the growth in the number of research centers, coupled with the growing number of diagnostic tests for cancer, is expected to drive the demand for molecular cytogenetics in this end-user segment.

North America accounted for the largest share of the molecular cytogenetics industry in 2022.

The molecular cytogenetics market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America has established itself as a primary contributor, holding the greatest market share in the molecular cytogenetics industry. The region's strong R&D infrastructure has facilitated swift adoption of cutting-edge techniques and platforms. Additionally, North America hosts numerous key companies within this sector, equipped with substantial expertise, resources, and well-established distribution networks, bolstering the region's dominance in the market. Moreover, the substantial impact of chronic conditions on the regional healthcare system serves as a significant driver for the market's growth.

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US). These players' market leadership arises from their extensive product ranges and wide-reaching global presence. These dominant entities enjoy various advantages such as robust marketing and distribution networks, sizable research and development budgets, and firmly established brand recognition.

Scope of the Molecular Cytogenetics Industry

This report categorizes the molecular cytogenetics market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Kits & Reagents
• Testing Kits
• Probes
• Fluorescent Affinity Reagents
• Other Kits & Reagents
• Instruments
• Consumables
• Software & Services

By Technique

• Comparative Genomic Hybridization
• Array-Based Comparative Genomic Hybridization
• Standard Comparative Genomic Hybridization
• Fluorescence In-Situ Hybridization
• Chromogenic In-Situ Hybridization
• Other Techniques

By Application

• Genetic Disorders
• Cancer
• Personalized Medicine
• Other Applications

By End User

• Clinical & Research Laboratories
• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments of Molecular Cytogenetics Industry

• In March 2023, Thermo Fisher Scientific & Pfizer partner to expand localized access to next generation sequencing-based testing for cancer patients in international markets.
• In January 2023, Agilent announced the acquisition of Avida Biomed, a high-performance NGS target enrichment workflow developer for cancer research.
• In November 2022, Danaher Corporation, a global science and technology innovator, announced that it has entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation.
• In May 2021, Roche acquires GenMark as it aims to expand its portfolio of molecular cytogenetics .

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst